ARYA Sciences Acquisition Corp. (ARYA) announced by press release this afternoon that their combination with Immatics Biotechnologies GmbH has been approved. The shares of common stock and warrants are expected to begin trading under the tickers (IMTX) and (IMTXW).
Additionally, none of the shareholders elected to redeem their shares in connection with the shareholder vote. But this was expected since ARYA’s share price has been trading at roughly $16.77, well above estimated trust value. Nonetheless, this is a strong result.
Backed by Perceptive Advisors, one of the most well known life sciences hedge funds, ARYA’s combination with Immatics looked like a well received combination when it was announced in March 2020 and expectations for success have only gained steam since then.
This transaction is expected to close in the coming few days.
ADVISORS
- Goldman Sachs International and SVB Leerink are acting as lead financial advisors.
- BofA Securities and Kempen are serving as financial advisors to Immatics.
- Jefferies LLC is acting as lead financial and capital markets advisor to Arya as well as sole private placement agent.
- Chardan Capital Markets LLC is also serving as advisor to Arya.
- Goodwin Procter LLP and CMS Legal Services EEIG are acting as legal counsel to Immatics.
- Kirkland & Ellis LLP is serving as legal counsel to Arya.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...